Cipla (CPLFY) EPS without NRI: $0.58 (TTM As of Mar. 2026)


What is Cipla EPS without NRI?

Cipla CPLFY 92 EPS without NRI is $0.58 as of Mar. 2026. GuruFocus rates CPLFY with a GF Score™ of 92/100. The stock has 5 warning signs investors should review. Among 787 Drug Manufacturers companies, Cipla ranks better than 53.49% on this metric.

Cipla's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.08. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.58.

During the past 12 months, Cipla's average earnings per share (NRI) Growth Rate was -26.00% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 11.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 15.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cipla's EPS without NRI or its related term are showing as below:

CPLFY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4   Med: 12.5   Max: 29.7
Current: 11.5

During the past 13 years, Cipla's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 29.70% per year. The lowest was -4.00% per year. And the median was 12.50% per year.

CPLFY's 3-Year EPS without NRI Growth Rate is ranked better than
53.49% of 787 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs CPLFY: 11.50

Cipla's EPS (Diluted) for the three months ended in Mar. 2026 was $0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.54.

Cipla's EPS (Basic) for the three months ended in Mar. 2026 was $0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.54.


Cipla  (OTCPK:CPLFY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cipla EPS without NRI Related Terms


Cipla EPS without NRI Historical Data

* Premium members only.

The historical data trend for Cipla's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla EPS without NRI Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.43 0.62 0.76 0.53

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.19 0.19 0.12 0.08

CPLFY vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipla PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cipla's PE Ratio without NRI falls into.



Cipla EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.58 mean?
Cipla (CPLFY) has a EPS without NRI of $0.58 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cipla and its competitors. According to the industry distribution chart, Cipla ranks #366 out of 787 companies in the Drug Manufacturers industry, placing it in the top 46.5%.
Is Cipla's EPS without NRI too high?
Cipla's current EPS without NRI is $0.58. The Drug Manufacturers industry median EPS without NRI is 9.70. Cipla's value of $0.58 is 94% below this industry median. Based on the distribution chart, Cipla ranks #366 out of 787 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cipla has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #366 out of 787 companies for EPS without NRI. This puts Cipla in the upper half of its industry. The industry median EPS without NRI is 9.70. Cipla's value of $0.58 is 94% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current EPS without NRI of $0.58 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current EPS without NRI is $0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current EPS without NRI of $0.58. The current EPS without NRI is $0.58 and 94% below the Drug Manufacturers industry median of 9.70. Cipla's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cipla (CPLFY), the current EPS without NRI is $0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.